Drugs / Etribnabdione
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06774040 | Jan 2026 → Mar 2027 expected | peripheral arterial disease | VivaCell Biotechnology España | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Etribnabdione | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06774040 ↗ |